2.930SEK-0.85%Mkt Cap: 399.27M SEKP/E: —Last update: 2026-05-13
Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, wh…
Industry Peers
Biotechnologyloading…
Indicators:|
Key Statistics
Valuation
P/E (Trailing)—
P/E (Forward)-24.92
PEG—
P/B3.81
P/S—
EV/EBITDA-4.84
EV/Revenue—
EPS (TTM)-0.67
EPS (Forward)-0.12
Cash Flow & Leverage
FCF Yield-15.54%
FCF Margin—
Operating CF-72.25M SEK
CapEx (TTM)57.00K SEK
Net Debt/EBITDA0.47
Net Debt-33.20M SEK
Technical
SMA 503.000 (-2.3%)
SMA 2003.256 (-10.0%)
Beta—
S&P 52W Chg24.23%
Avg Vol (30d)746.02K
Avg Vol (10d)582.66K
Technical Indicators
RSI (14)45.5
MACD-0.0327
MACD Signal-0.0123
MACD Hist.-0.0204
BB Upper3.406 SEK
BB Middle3.072 SEK
BB Lower2.738 SEK
BB Width21.77%
ATR (14)0.1601 SEK
Vol Ratio (20d)0.60x
52W Range
2.53015% of range5.230
52W High5.230 SEK
52W Low2.530 SEK
Profitability
Gross Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
Oper. Margin0.00%
ROE-76.66%
ROA-68.12%
Revenue Growth—
Earnings Growth—
Balance Sheet
Debt/Equity0.01
Current Ratio2.81
Quick Ratio2.70
Book Value/Sh0.7840 SEK
Cash/Share0.2690 SEK
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 SEK
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Ownership
Shares Out.133.54M
Float116.72M
Insiders16.66%
Institutions21.83%
Analyst Consensus
Rating0.0 (Hold)
Target (Mean)5.600 SEK
Target Range3.700 SEK – 8.500 SEK
# Analysts4
Company
Market Cap399.27M SEK
Enterprise Value343.50M SEK
Revenue (TTM)—
Gross Profit0 SEK
Net Income (TTM)-76.25M SEK
Revenue/Share—
Fiscal Year EndDec 2019
MR QuarterMar 2026
Employees—
Last Price2.930 SEK
CountrySE
SectorHealthcare
IndustryBiotechnology
ISINUS00444E1038